Development of a Competency Framework for Medical Affairs Professionals in Australasia [0.03%]
亚太地区医药事务专业人员胜任力模型的构建与发展
Andrew Weekes,Matthew Britland,Cathey Saha et al.
Andrew Weekes et al.
Background and objectives: Medical Affairs (MA) plays a critical role in bridging the gap between research, clinical practice and business strategy. With the rapid growth in this field, it is essential to have a competenc...
Acceptance and Utilization of Real-World Evidence among Cancer Care Physicians in the USA: A National Survey [0.03%]
美国癌症护理医师对真实世界证据的接受度和应用情况:一项全国性调查研究
Thomas M Porter,Kathleen M Andersen,Wencesley Paez et al.
Thomas M Porter et al.
Background and objective: Regulatory agencies and policy makers increasingly recognize real-world evidence (RWE) as a valuable complement to randomized controlled trials (RCTs) in oncology, yet data on how US physicians w...
The Utilization, Reimbursement, and Cost of Targeted Therapies for Duchenne Muscular Dystrophy (DMD) in US Medicaid Programs: A Descriptive Trend Analysis from 2017 to 2022 [0.03%]
美国医疗补助计划中杜氏肌营养不良症靶向治疗的利用、报销和成本:2017至2022年的描述性趋势分析
Yazeed Ghawaa,Alex C Lin,Jeff Jianfei Guo
Yazeed Ghawaa
Background: Duchenne muscular dystrophy (DMD) is a rare hereditary neuromuscular disorder caused by mutations in the dystrophin gene, leading to progressive muscle deterioration, loss of ambulation, and reduced life expec...
Exosomes as Emerging Therapeutic Platforms in Neurological and Psychiatric Disorders [0.03%]
外泌体在神经和精神系统疾病治疗中的新兴作用
Ram Mohan Ram Kumar,Logesh Rajan,Saravana Babu Chidambaram
Ram Mohan Ram Kumar
Exosomes, small extracellular vesicles (sEVs) that range in Size from 30 to 150 nm in diameter, have emerged as crucial mediators of intercellular communication within the central nervous system (CNS). They play significant roles in the pat...
Survey on the Role of Comparative Efficacy Studies Required for Biosimilar Monoclonal Antibody Approval in Japan to Justify the Quality Attribute Differences Between Biosimilars and Their Reference Products Based on the Pharmaceuticals and Medical Devices Agency (PMDA) Assessments [0.03%]
基于日本药品和医疗器械局(PMDA)的评估,调查比较效力研究在日本生物类似药单克隆抗体批准中的作用以证明生物类似药及其参照药之间的质量属性差异合理性
Kanoko Goto,Aya Hariu,Ryosuke Kuribayashi
Kanoko Goto
Background and objective: Since the approval of the first biosimilar monoclonal antibody (mAb) in 2014, 18 biosimilar mAbs have been approved in Japan as of December 2023. These biosimilar mAbs are typically developed usi...
Embedding Implementation Science in Clinical Trials: A Framework for Academic-Life Science Partnerships [0.03%]
临床试验中的实施科学嵌入:学术-生命科学合作伙伴关系框架
Tyler L Cope,Emily C OBrien,Neha J Pagidipati et al.
Tyler L Cope et al.
Implementation science offers a systematic approach to bridging the gap between research and clinical practice by promoting the adoption, scale-up, and sustainment of evidence-based therapies. Historically, academic implementation science e...
Telehealth and Pharmacotherapy: The Role of Synchronous and Novel Asynchronous Digital Health Tools in Psychiatry [0.03%]
远程医疗与药疗:精神病学中同步和新型异步数字健康工具的作用
Soumya Choudhary,Benjamin Nelson,Nev Jones et al.
Soumya Choudhary et al.
Digital psychiatry tools are increasingly woven into routine care, not only to support pharmacotherapy but also to deliver psychotherapy, sustain engagement and redesign clinical workflows. This narrative review synthesises synchronous (e.g...
Awareness and Experience of Direct Healthcare Professional Communication and Risk Management Plan Educational Material among Healthcare Professionals in Finland [0.03%]
芬兰卫生专业人员对直接卫生专业人员沟通和风险管理计划教育材料的意识和体验
Heli A Sandberg,Andreas B Sandberg,Anu J Aallos et al.
Heli A Sandberg et al.
BACKGROUND AND OBJECTIVES: Additional risk minimization measures (aRMMs), such as direct healthcare professional communication (DHPC) and risk management plan (RMP) educational materials, are required for certain medicinal products to mitig...
A Framework for Considering the Role of the Public Sector in R&D of Health Technology [0.03%]
公共卫生技术研究与发展中的公共部门角色的考量框架
Juan Carlos Rejon-Parrilla,David Epstein,Jorge Mestre-Ferrandiz et al.
Juan Carlos Rejon-Parrilla et al.
The development of health technologies involves complex, costly, and risky investments, with significant contributions from both public and private sectors. Recent EU pharmaceutical directives propose transparency on public funding to aid p...
Shubhadeep Sinha,Ruby Raphael
Shubhadeep Sinha
The global pharmaceutical landscape is undergoing a profound shift with the rise of biosimilars-biologic medical products that are highly similar to original biologics but manufactured by different companies. Biological therapies encompass ...